imbb mobile logo
 
ΙΤΕ  /
Αγγελική Μαγκλάρα

Αγγελική Μαγκλάρα

Αναπληρώτρια Καθηγήτρια Κλινικής Χημείας, Τμήμα Ιατρικής, Σχολή Επιστημών Υγείας, Πανεπιστήμιο Ιωαννίνων
Ηλ. Ταχυδρομείο
Αυτή η διεύθυνση ηλεκτρονικού ταχυδρομείου προστατεύεται από τους αυτοματισμούς αποστολέων ανεπιθύμητων μηνυμάτων. Χρειάζεται να ενεργοποιήσετε τη JavaScript για να μπορέσετε να τη δείτε.
Τηλέφωνο
+30 26510 07818
Fax
+30 2651 007077
Ιστοσελίδα Εργαστηρίου
https://www.bri.forth.gr/magklara
 

H Δρ. Αγγελική Mαγκλάρα είναι Αναπληρώτρια Καθηγήτρια Κλινικής Χημείας στο Τμήμα Ιατρικής της Σχολής Επιστημών Υγείας του Πανεπιστημίου Ιωαννίνων. Έλαβε το βασικό της Πτυχίο από το Τμήμα Βιολογίας  και στη συνέχεια Μεταπτυχιακό Δίπλωμα Ειδίκευσης στην Κλινική Βιοχημεία από το Τμήμα Χημείας του Εθνικού και Καποδιστριακού Πανεπιστημίου Αθηνών. Η Δρ. Μαγκλάρα διεκπεραίωσε τη διδακτορική της διατριβή στο Τμήμα Εργαστηριακής Ιατρικής και Παθοβιολογίας στο Πανεπιστήμιο του Τορόντο, στον Καναδά, με θέμα τον χαρακτηρισμό νέων μελών της γονιδιακής οικογένειας των ανθρώπινων καλλικρεϊνών και την αξιολόγησή τους ως πιθανούς βιοδείκτες όγκων. Στη συνέχεια μετέβη για τη μεταδιδακτορική της εκπαίδευση στο Εργαστήριο Βιολογίας Υποδοχέων και Γονιδιακής Έκφρασης στα Εθνικά Ινστιτούτα Υγείας (NCI/ΝΙΗ) στην Bethesda, Maryland, USA, όπου μελέτησε τους μηχανισμούς δράσης του υποδοχέα της προγεστερόνης στον καρκίνο του μαστού. Η Δρ. Μαγκλάρα συνέχισε την ερευνητική της καριέρα στο Πανεπιστήμιο της Καλιφόρνια στο Σαν Φρανσίσκο (UCSF), όπου ασχολήθηκε με τη μελέτη των μηχανισμών της επιγενετικής ρύθμισης των γονιδίων των οσφρητικών υποδοχέων. Το 2012 της απονεμήθηκε το Marie Curie Career Integration Grant και μετακόμισε στην Ελλάδα, όπου ξεκίνησε την ερευνητική της ομάδα στο Ινστιτούτο Βιοϊατρικών Ερευνών του ΙΤΕ στα Ιωάννινα. Το 2014 ανέλαβε τα ακαδημαϊκά της καθήκοντα στο Πανεπιστήμιο των Ιωαννίνων. Τα τρέχοντα ερευνητικά της ενδιαφέροντα εστιάζονται στον χώρο της επιγενετικής του καρκίνου, στα καρκινικά βλαστικά κύτταρα και στην ανάπτυξη και εφαρμογή υγρών βιοψιών σε ογκολογικούς ασθενείς.

Full CV
  1. Kordias D, Kostara CE,  Papadaki S,  Verigos J, Bairaktari E, Magklara A. Omics Analysis of Chemoresistant Triple Negative Breast Cancer Cells Reveals Novel Metabolic Vulnerabilities. Cells 2022;11(17):2719. doi: 10.3390/cells11172719.
  2. Papadaki S, Magklara A. Regulation of Metabolic Plasticity in Cancer Stem Cells and Implications in Cancer Therapy. Cancers(Basel) 2022;14(23):5912. doi:10.3390/ cancers14235912.
  3. Verigos J, Kordias D, Papadaki S, Magklara A. Transcriptional Profiling of Tumorspheres Reveals TRPM4 as a Novel Stemness Regulator in Breast Cancer. Biomedicines. 2021;9(10):1368. doi: 10.3390/biomedicines9101368.
  4. Verigos J, Karakaidos P, Kordias D, Papoudou-Bai A, Evangelou Z, Harissis HV, Klinakis A, Magklara A. The Histone Demethylase LSD1/ΚDM1A Mediates Chemoresistance in Breast Cancer via Regulation of a Stem Cell Program. Cancers 2019; 11(10).
  5. Kastrisiou M, Zarkavelis G, Kougioumtzi A, Sakaloglou P, Kostoulas C, Georgiou I, Batistatou A, Pentheroudakis G, Magklara A. Development and Validation of a Targeted 'Liquid' NGS Panel for Treatment Customization in Patients with Metastatic Colorectal Cancer. Diagnostics (Basel). 2021;11(12):2375. doi: 10.3390/diagnostics11122375.
  1. Papadaki S, Magklara A. Regulation of Metabolic Plasticity in Cancer Stem Cells and Implications in Cancer Therapy. Cancers(Basel) 2022;14(23):5912. doi:10.3390/ cancers14235912.
  2. Kordias D, Kostara CE,  Papadaki S,  Verigos J, Bairaktari E, Magklara A. Omics Analysis of Chemoresistant Triple Negative Breast Cancer Cells Reveals Novel Metabolic Vulnerabilities. Cells 2022;11(17):2719. doi: 10.3390/cells11172719.
  3. Georgakopoulou C, Thomos D, Tsolis T, Ypsilantis K, Plakatouras JC, Kordias D, Magklara A, Kouderis C, Kalampounias AG, Garoufis A. Synthesis, characterization, interactions with the DNA duplex dodecamer d(5'-CGCGAATTCGCG-3')2 and cytotoxicity of binuclear η6-arene-Ru(II) complexes. Dalton Trans 2022;51(36):13808-13825. doi: 10.1039/d2dt02304k.
  4. Iatridis N, Kougioumtzi A, Vlataki K, Papadaki S, Magklara A. Anti-Cancer Properties of Stevia rebaudiana; More than a Sweetener. 2022;27(4):1362. doi: 10.3390/molecules27041362.
  5. Kastrisiou M, Zarkavelis G, Kougioumtzi A, Sakaloglou P, Kostoulas C, Georgiou I, Batistatou A, Pentheroudakis G, Magklara A. Development and Validation of a Targeted 'Liquid' NGS Panel for Treatment Customization in Patients with Metastatic Colorectal Cancer. Diagnostics (Basel). 2021;11(12):2375. doi: 10.3390/diagnostics11122375.
  6. Verigos J, Kordias D, Papadaki S, Magklara A. Transcriptional Profiling of Tumorspheres Reveals TRPM4 as a Novel Stemness Regulator in Breast Cancer. Biomedicines. 2021;9(10):1368. doi: 10.3390/biomedicines9101368.
  7. Tsolis T, Nikolaou N, Ypsilantis K, Kougioumtzi A, Kordias D, Magklara A, Garoufis A. Synthesis, characterization, interactions with 9-MeG and cytotoxic activity of heterobimetallic RuII-PtII complexes bridged with 2, 2'-bipyrimidine. J Inorg Biochem. 2021;219:111435.
  8. Verigos J, Karakaidos P, Kordias D, Papoudou-Bai A, Evangelou Z, Harissis HV, Klinakis A, Magklara A. The Histone Demethylase LSD1/ΚDM1A Mediates Chemoresistance in Breast Cancer via Regulation of a Stem Cell Program. Cancers 2019; 11(10).
  9. Karakaidos P, Verigos I, Magklara A. LSD1/KDM1A, a Gate-Keeper of Cancer Stemness and a Promising Therapeutic Target. Cancers 2019; 11(12).
  10. Kastrisiou M, Zarkavelis G, Pentheroudakis G, Magklara A. Clinical Application of Next-Generation Sequencing as A Liquid Biopsy Technique in Advanced Colorectal Cancer: A Trick or A Treat? Cancers 2019;11(10).
  11. Touloupi K, Küblbeck J, Magklara A, Molnár F, Reinisalo M, Konstandi, Honkakoski P, Pappas P The basis for strain-dependent rat aldehyde dehydrogenase 1A7 (ALDH1A7) gene expression. Molecular Pharmacology 2019; 96(5): 655-663.
  12. Le Gros MA, Clowney EJ, Magklara A, Yen A, Markenscoff-Papadimitriou E, Colquitt B, Myllys M, Kellis M, Lomvardas S, Larabell CA. Soft X-Ray Tomography Reveals Gradual Chromatin Compaction and Reorganization during Neurogenesis In Vivo. Cell Rep. 2016 Nov 15;17(8):2125-2136.
  13. Verigos J and Magklara A. Revealing the Complexity of Breast Cancer by Next Generation Sequencing. Cancers (Basel) 2015;7(4):2183-200.
  14. Lyons DB, Magklara A, Goh T, Sampath S, Schaefer A, Schotta G, Lomvardas S. Heterochromatin-Mediated Gene Silencing Facilitates the Diversification of Olfactory Neurons. Cell Rep.2014;9:1-9.
  15. Kougioumtzi A, Tsaparas P, Magklara A. Deep sequencing reveals new aspects of progesterone receptor signaling in breast cancer cells. PLoS One. 2014 Jun 4;9(6):e98404.
  16. Magklara A and Lomvardas S. Stochastic gene expression in mammals: Lessons from Olfaction. Trends in Cell Biology 2013 Sep;23(9):449-56.
  17. Johnson MA, Tsai L, Roy DS, Valenzuela DH, Mosley C, Magklara A, Lomvardas S, Liberles SD, Barnea G. Neurons expressing trace amine-associated receptors project to discrete glomeruli and constitute an olfactory subsystem. Proc Natl Acad Sci U S A. 2012 Aug 14;109(33):13410-5.
  18. Clowney EJ, Magklara A, Colquitt BM, Pathak N, Lane RP, Lomvardas S. High-throughput mapping of the promoters of the mouse olfactory receptor genes reveals a new type of mammalian promoter and provides insight into olfactory receptor gene regulation. Genome Res. 2011 Aug;21(8):1249-59
  19. Magklara A, Yen A, Colquitt BM, Clowney EJ, Allen W, Markenscoff-Papadimitriou E, Evans ZA, Kheradpour P, Mountoufaris G, Carey C, Barnea G, Kellis M, Lomvardas S. An epigenetic signature for monoallelic olfactory receptor expression. Cell. 2011 May 13;145(4):555-70.
  20. Lee SC, Magklara A, Smith CL. HDAC activity is required for efficient core promoter function at the mouse mammary tumor virus promoter. J Biomed Biotechnol. 2011;2011:416905.
  21. Magklara A, Smith CL. A composite intronic element directs dynamic binding of the progesterone receptor and GATA-2. Mol Endocrinol. 2009;23:61-73.
  22. Yousef GM, Obiezu CV, Luo LY, Magklara A, Borgoño CA, Kishi K, Memari N, Michael IP, Sidiropoulos M, Kurlender L, Economopoulou K, Kapadia C, Komatsu N, Petraki C, Elliott M, Scorilas A, Katsaros D, Levesque1 MA, Diamandis EP. Human Tissue Kallikreins: From Gene Structure to Function and Clinical Applications. Adv Clin Chem 2005;39:11-79
  23. Michael IP, Sotiropoulou G, Pampalakis G, Magklara A, Ghosh M, Wasney G, Diamandis EP. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J Biol Chem. 2005;280:14628-35.
  24. Sauter ER, Lininger J, Magklara A, Hewett JE, Diamandis EP. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk. Int J Cancer. 2004;108:588-91.
  25. Kapadia C, Yousef GM, Mellati AA, Magklara A, Wasney GA, Diamandis EP. Complex formation between human kallikrein 13 and serum protease inhibitors. Clin Chim Acta 2004;339:157-67.
  26. Magklara A, Mellati AA, Wasney GA, Little SP, Sotiropoulou G, Becker GW, Diamandis EP. Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors. Biochem Biophys Res Commun. 2003;307:948-55.
  27. Yousef GM, Scorilas A, Magklara A, Memari N, Ponzone R, Sismondi P, Abd Ellatif M, and Diamandis EP. The androgen regulated gene human kallikrein 15 (KLK15) is an independent and favorable prognostic marker for breast cancer. Br J Cancer 2002;87:1294-300.
  28. Sauter ER, Welch T, Magklara A, Klein G, Diamandis EP. Ethnic variation in kallikrein expression in nipple aspirate fluid. Int J Cancer.  2002 ;100:678-82.
  29. Magklara A, Brown TJ and Diamandis EP. Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3. Int J Cancer.2002;100: 507-14.
  30. Magklara A, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Danese S, Diamandis EP. The human KLK8 (neuropsin/ovasin) gene: Identification of two novel slice variants and its prognostic value in ovarian cancer. Clin Cancer Res. 2001;7:806-11.
  31. Scorilas A, Magklara A, Hoffman BR, Bromberg RM, Bjartell A and Diamandis EP. Highly sensitive array analysis using time resolved fluorescence and a novel streptavidin-based reagent. Analytical Sciences 2001;17(suppl):i547-i551.
  32. Yousef GM, Magklara A and Diamandis EP. Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies Cancer Res. 2001;61:3425-31.
  33. Obiezu CV, Scorilas A, Magklara A, Thornton MH, Wang CY, Stanczyk FZ, Diamandis EP. Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001;86:1558-61.
  34. Diamandis EP, Yousef GM, Luo LY, Magklara A and Obiezu CV. The new human kallikrein gene family-implications in carcinogenesis. Trend Endocrinol Metab 2000;11:54-60.
  35. Yousef GM, Magklara A and Diamandis KLK12 is a novel serine protease and a new member of the human kallikrein gene family- Differential expression in breast cancer. Genomics, 2000;69:331-41.
  36. Yousef GM, Scorilas A, Magklara A, Soosaipillai A, Diamandis EP. The PRSS6 gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family-genomic characterization, mapping, tissue expression and hormonal regulation. Gene, 2000;254:119-128.
  37. Magklara A, Scorilas A, Stephan C, Kristiansen GO, Hauptmann S, Jung K and Diamandis EP. Decreased concentrations of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) in malignant vs non-malignant prostatic tissue. Urology, 2000;56:527-32.
  38. Magklara A, Cheung CC, Asa SL, Diamandis EP. Expression of prostate-specific antigen and human glandular kallikrein 2 in the thyroid gland. Clinica Chimica Acta, 2000;300:171-80.
  39. Obiezu CV, Giltay EJ, Magklara A, Scorilas A, Gooren L, Yu H, Diamandis EP. Dramatic suppression of plasma and urinary prostate specific antigen and human glandular kallikrein by antiandrogens in male-to-female transsexuals. J Urol 2000;163:802-5.
  40. Obiezu CV, Giltay EJ, Magklara A, Scorilas A, Gooren L, Yu H, Howarth DJC and Diamandis EP. Serum and urinary prostate specific antigen and urinary human glandular kallikrein concentration are significantly elevated after testosterone administration in female to male transsexuals. Clinical Chemistry 2000;46:859-862.
  41. Zand Rosenberg RS, Grass L, Magklara A, Jenkins DJA and Diamandis EP. Is ICI 182-780 an anti-progestin in addition to being an anti-estrogen? Breast Cancer Res Treat 2000;60:1-8.
  42. Magklara A, Grass L, Diamandis EP. Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate specific antigen (PSA) in breast cancer cell lines. Breast Cancer Res Treat 2000;59:263-70.
  43. Nam RK, Diamandis EP, Toi A, Trachtenberg J, Magklara A, Scorilas A, Papanastasiou PA, Jewett MAS and Narod SA. Serum human glandular kallikrein (hK2) protease levels predict the presence of prostate cancer among men with elevated prostate specific-antigen. Journal of Clinical Oncology 2000;18:1036-42.
  44. Black MH, Magklara A, Obiezu CV, Levesque MA, Sutherland DJA, Tindall DJ, Young CYF, Sauter ER, Diamandis EP. Expression of a prostate associated protein, human glandular kallikrein (hK2) in breast tumors and in normal breast secretions. Br J Cancer 2000;82:361
  45. Magklara A, Scorilas A, Catalona WJ, Diamandis EP. The combination of human glandular kallikrein (hK2) and free PSA enhances the discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately elevated total PSA levels. Clinical Chemistry 1999;45:1960-6.
  46. Magklara A, Scorilas A, López-Otín C, Diamandis Human glandular kallikrein (hK2) in breast milk, amniotic fluid and breast cyst fluid. Clinical Chemistry, 1999;45:1774-80.
  47. Black MH, Magklara A, Obiezu CV, Melegos DN, Diamandis EP. Development of an ultrasensitive immunoassay for human glandular kallikrein (hK2) with no cross reactivity from prostate specific antigen (PSA). Clinical Chemistry 1999;45:790-9.
Ετικέτες

Γρήγοροι Σύνδεσμοι

Εσωτερική Χρήση